COST-EFFECTIVENESS OF TELAPREVIR COMBINATION THERAPY COMPARED TO PEGINTERFERON WITH RIBAVIRIN ALONE FOR NAIVE AND TREATMENT EXPERIENCED PATIENTS WITH GENOTYPE 1 CHRONIC HEPATITIS C IN POLAND

被引：0
|
作者：
Kaczor, M. P. [1 ]
Wojcik, R. [2 ]
Pawlik, D. [2 ]
Skrzekowska-Baran, I [3 ]
Tronczynski, K. [3 ]
机构：
[1] Jagiellonian Univ, Coll Med, Krakow, Poland
[2] Aestimo Sc, Krakow, Poland
[3] Janssen Cilag Polska, Warsaw, Poland
来源：
VALUE IN HEALTH | 2013年 / 16卷 / 07期
关键词：
D O I：
10.1016/j.jval.2013.08.217
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A359 / A360
页数：2
相关论文
共 50 条
  • [21] THE COST-EFFECTIVENESS OF HEPATITIS C TREATMENTS IN TREATMENT NAIVE GENOTYPE 1 PATIENTS
    McGinnis, J. J.
    Hay, J. W.
    VALUE IN HEALTH, 2014, 17 (03) : A274 - A274
  • [22] The cost-effectiveness analysis of combination of peginterferon alfa-2a and ribavirin versus combination of peginterferon alfa-2b and ribavirin in chronic hepatitis C in Poland
    Orlewska, E
    VALUE IN HEALTH, 2004, 7 (03) : 356 - 356
  • [23] COST EFFECTIVENESS OF BOCEPREVIR PLUS PEGINTERFERON ALPHA AND RIBAVIRIN VERSUS TELAPREVIR PLUS PEGINTERFERON ALFA AND RIBAVIRIN IN THE TREATMENT OF CHRONIC HEPATITIS C (CHC) IN PREVIOUSLY UNTREATED GENOTYPE I PATIENTS
    Fonseca, M.
    Garran, V
    Araujo, G. T.
    VALUE IN HEALTH, 2012, 15 (07) : A328 - A328
  • [24] Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C
    Camma, Calogero
    Petta, Salvatore
    Cabibbo, Giuseppe
    Ruggeri, Matteo
    Enea, Marco
    Bruno, Raffaele
    Capursi, Vincenza
    Gasbarrini, Antonio
    Alberti, Alfredo
    Craxi, Antonio
    JOURNAL OF HEPATOLOGY, 2013, 59 (04) : 658 - 666
  • [25] COST-EFFECTIVENESS ANALYSIS OF A PERSONALIZED THERAPY FOR GENOTYPE 1, NAIVE, CHRONIC HEPATITIS C PATIENTS IN ITALY
    Iannazzo, S.
    Colombatto, P.
    Bonino, F.
    Brunetto, M. R.
    VALUE IN HEALTH, 2014, 17 (07) : A366 - A366
  • [26] A cost-effectiveness model to personalize antiviral therapy in naive patients with genotype 1 chronic hepatitis C
    Iannazzo, Sergio
    Colombatto, Piero
    Ricco, Gabriele
    Oliveri, Filippo
    Bonino, Ferruccio
    Brunetto, Maurizia R.
    DIGESTIVE AND LIVER DISEASE, 2015, 47 (03) : 249 - 254
  • [27] Efficacy, Safety and UK Cost-Effectiveness in Treatment-Naive Patients with F2 Fibrosis Treated with Telaprevir (TVR; T) in Combination with Peginterferon (P) and Ribavirin (R) vs Peginterferon and Ribavirin Alone
    Jacobson, Ira
    Baldini, Alessandra
    DeMasi, Ralph
    Gavart, Sandra
    Luo, Donghan
    Mrus, Joseph
    Witek, James
    Marcellin, Patrick
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2012, 107 : S179 - S180
  • [28] Cost Effectiveness of Peginterferon α-2a and Peginterferon α-2b Combination Regimens in Genotype-1 Naive Patients with Chronic Hepatitis C
    Gheorghe, Liana
    Baculea, Simona
    HEPATO-GASTROENTEROLOGY, 2010, 57 (101) : 939 - 944
  • [29] Effectiveness of peginterferon and ribavirin in naive patients with chronic hepatitis C in clinical practice
    Casiraghi, Maria Antonietta
    Terreni, Natalia
    Mandelli, Giovanna
    Spinzi, Giancarlo
    Minoli, Giorgio
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2006, 101 (09): : S153 - S153
  • [30] Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden
    Bernfort, Lars
    Sennfalt, Karin
    Reichard, Olle
    SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2006, 38 (6-7) : 497 - 505
12345